Arrowstreet Capital
NERV icon

Arrowstreet Capital’s Minerva Neurosciences NERV Stock Holding History

Arrowstreet Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-26,177
Closed -$666K – 2455
2020
Q3 		$666K Sell
26,177
-26,177
-50% -$708K ﹤0.01% 1934
2020
Q2 		$1.51M Buy
+52,354
New +$3.07M ﹤0.01% 1596
2020
Q1 		– Sell
-11,857
Closed -$674K – 2027
2019
Q4 		$674K Buy
+11,857
New +$523K ﹤0.01% 1430

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's NERV Position: Q4 2020 in Review

Arrowstreet Capital sold out of Minerva Neurosciences (NERV) in Q4 2020, closing a stake of 26,177 shares — an estimated $666K sold.

Arrowstreet Capital first reported a position in NERV in Q4 2019 and held it in 3 quarters. The position peaked at $1.51M in Q2 2020. 76 funds tracked by Wall St. Rank hold NERV as of Q4 2020.

  • Arrowstreet Capital reported no remaining Minerva Neurosciences position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 26,177 Minerva Neurosciences shares in Q4 2020, an estimated $666K.
  • Arrowstreet Capital first reported a position in Minerva Neurosciences in Q4 2019 and held it in 3 quarters.
  • Arrowstreet Capital's Minerva Neurosciences position peaked at $1.51M in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.